20S-Hydroxyvitamin D3, Noncalcemic Product of CYP11A1 Action on Vitamin D3, Exhibits Potent Antifibrogenic Activity in Vivo | Zendy

Andrzej Słomiński | Zendy; Zorica Janjetović | Zendy; Robert C. Tuckey | Zendy; Minh N. Nguyen | Zendy; Keka G. Bhattacharya | Zendy; Jin Wang | Zendy; Wěi Li | Zendy; Yan Jiao | Zendy; Weikuan Gu | Zendy; Monica Brown | Zendy; Arnold E. Postlethwaite | Zendy

Open Access

20S-Hydroxyvitamin D₃, Noncalcemic Product of CYP11A1 Action on Vitamin D₃, Exhibits Potent Antifibrogenic Activity in Vivo

Author(s) -

Andrzej Słomiński,

Zorica Janjetović,

Robert C. Tuckey,

Minh N. Nguyen,

Keka G. Bhattacharya,

Jin Wang,

Wěi Li,

Yan Jiao,

Weikuan Gu,

Monica Brown,

Arnold E. Postlethwaite

Publication year - 2013

Publication title -

the journal of clinical endocrinology and metabolism

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.206

H-Index - 353

eISSN - 1945-7197

pISSN - 0021-972X

DOI - 10.1210/jc.2012-3074

Subject(s) - in vivo , vitamin d and neurology , chemistry , endocrinology , medicine , in vitro , vitamin , pharmacology , microbiology and biotechnology , biochemistry , biology

There is no effective treatment for systemic sclerosis and related fibrosing diseases. Recently the action of CYP11A1 on vitamin D(3) was shown to produce biologically active 20S-hydroxyvitamin D [20(OH)D(3)] and 20,23(OH)(2)D(3), 20,22(OH)(2)D(3), and 17,20,23(OH)(3)D(3).

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research